By monitoring the serum ctDNA mutational profile using NGS, the present clinical trial aims to elucidate the correlation between the postoperative ctDNA status and the prognosis of patients with early and intermediate-stage colorectal cancer, and explore the possibility of clinical utility of serum ctDNA as a clinical index to predict postoperative relapse.

Colorectal cancer (CRC), as one of the common malignant tumors with high mobidity and mortality, is a major health threat in China.Surgical resection is the conventional treatment for early and intermediate stageCRC, however, it is not curative and postoperative recurrenceremains a clinical dilemma.Early detection of recurrence by serum tumor biomarkers and Computed Tomography (CT) during follow-up can improve the overall survival of patients with surgical resection. Nevertheless, thecurrently available tumor biomarkers have limited sensitivity and specificity, and CT is associated with radiation exposure. Therefore, there is a need for a more effective and feasible methodfor the prediction of postoperative recurrence.

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA with an average size of 170bp, mixed with cell free DNA (cfDNA) of other sources in blood circulation. Although the mechanisms of its release have not been fully addressed, apoptosis and/or necrosis of tumor cells and serum exosome are considered as its main source, which makes it a genomic reservoir of different tumor clones. Also, as its half-life is up to hours, ctDNA is reflecting the most up-to-date status of tumor genome. Hence, it allows for noninvasive molecular characterization of tumors,which can be qualitative, quantitative and used for disease monitoring.

The possibility of that ctDNA could be used to detect micrometastatic disease in patients received surgical resection was suggested in several studies. UsingNext Generation Sequencing (NGS),Newman et al. have shown that the serum level of ctDNA was correlated withtumor progress and prognosis in NSCLC. Isaac et al. demonstrated the postoperativectDNA level was associated with breast cancer progression, and it was more sensitive compared to CT scan for predicting the early relapse. Tie et al. examined the postoperative ctDNA level of 1046 plasma samples from a prospective cohort of 230 patients with resected stage II CRC by NGS, and their results demonstrated that recurrence happened in 79% of the patients with positive postoperative ctDNA at median follow-up of 27 months, versus 9.8% in the negative postoperative ctDNA group.

By monitoring the serum ctDNA mutational profile using NGS, the present clinical trial aims to elucidate the correlation between the postoperative ctDNA status and the prognosis of patients with early and intermediate-stage colorectal cancer, and explore the possibility of clinical utility of serum ctDNA as a clinical index to predict postoperative relapse.

Inclusion Criteria:

1. Male or female ≥ 18 years of age on the day of signing informed consent.
2. Patients must have histologically confirmed stage II/IIIcolorectal cancer.
3. Patients need to receive surgical resection.
4. Patients must have a performance status of ≤1 on the ECOG Performance Scale.
5. Patients must have survival of > 12 months after the index date
6. Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study.

Exclusion Criteria:

1. Patients received adjuvant treatment prior to the surgical resection.
2. Patients received blood transfusion two weeks before or during the surgical resection.
3. Patients who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C.
4. Patients who are pregnant.
5. Patients who are alcoholic or drug abusers.
6. Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.

Patients must have baseline evaluations performed prior to the study and must meet all inclusion and exclusion criteria. In addition, the patient must be thoroughly informed about all aspects of the study, including the study visit schedule and required evaluations and all regulatory requirements for informed consent. The written informed consent must be obtained from the patient prior to enrollment. The following criteria apply to all patients enrolled onto the study unless otherwise specified.